Company Profile
EirGenix is a contract development and manufacturing company in Taiwan and globally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services.
It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status.
Its portfolio also includes EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage, EG13074, indicated for the treatment of cancer and currently under Preclinical stage, TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage, EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage, and EG62054, a biosimilar, currently under Preclinical stage.
Additionally, it manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. Incorporated in 2012, the company is headquartered in New Taipei City, Taiwan.